Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 201–300 of 2,576
Role of complement in neurodegeneration and neuroinflammation
BONIFATI, D., & KISHORE, U. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.03.007 · Cited by 313
Presenilin-Mediated Modulation of Capacitative Calcium Entry
Yoo, A. S., Cheng, I., Chung, S., Grenfell, T. Z., Lee, H., Pack-Chung, E., Handler, M., Shen, J., Xia, W., Tesco, G., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)00066-0 · Cited by 312
“…phenotypes of FAD-associated mutations in the presenilins include increased levels of the 42 aminoSummary acid version of Ab (Ab42) in AD patients (Scheuner et al., 1996) as well as transfected cell lines and transgenicWe studied a novel function of the presenilins (PS1 and animals expressing FAD…”
BackgroundSelf-citation18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthe, C., Lent, R. W., Younkin, S., Younkin, L., Schiff, R., & Weksler, M. E. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305
Self-citationIntracellular Generation and Accumulation of Amyloid β-Peptide Terminating at Amino Acid 42
Wild-Bode, C., Yamazaki, T., Capell, A., Leimer, U., Steiner, H., Ihara, Y., & Haass, C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.26.16085 · Cited by 303
Lazarov, O., Lee, M., Peterson, D. A., & Sisodia, S. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09785.2002 · Cited by 302
“…and PS2) (Price and Sisodia, 1998; Selkoe, 2001); FAD-linked APP or presenilin variants cause disease by enhancing the levels, length, or fibrillogenic properties of A peptides (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997) and their subsequent deposition.”
BackgroundEarly onset familial Alzheimer’s disease: Mutation frequency in 31 families
Janssen, J. C., Beck, J. A., Campbell, T. A., Dickinson, A., Fox, N. C., Harvey, R. J., Houlden, H., Rossor, M. N., & Collinge, J. (2003) · Neurology · doi:10.1212/01.wnl.0000042088.22694.e3 · Cited by 301
Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasma
Vanderstichele, H., Kerschaver, E. V., Hesse, C., Davidsson, P., Buyse, M.-A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., & Vanmechelen, E. (2000) · Amyloid · doi:10.3109/13506120009146438 · Cited by 301
Golde, T. E., Eckman, C. B., & Younkin, S. G. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00043-0 · Cited by 244
Self-citationEvidence for glial-mediated inflammation in aged APPSW transgenic mice
Benzing, W. C., Wujek, J. R., Ward, E. K., Shaffer, D., Ashe, K. H., Younkin, S. G., & Brunden, K. R. (1999) · Neurobiology of Aging · doi:10.1016/s0197-4580(99)00065-2 · Cited by 299
Self-citationThe role of TNF and its receptors in Alzheimer's disease
Perry, R. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00291-3 · Cited by 297
β-Secretase Activity Increases with Aging in Human, Monkey, and Mouse Brain
Fukumoto, H., Rosene, D. L., Moss, M. B., Raju, S., Hyman, B. T., & Irizarry, M. C. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63159-8 · Cited by 294
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K., Høilund-Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 284
Microglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293
“Other cells, such as, astrocytes, olfactory ensheathing cells (OECs), and neurons, also contribute to degrading and clearing Aβ (Scheuner et al., 1996; Malm et al., 2010).”
BackgroundAchieving and Maintaining Cognitive Vitality With Aging
Fillit, H. M., Butler, R. N., O'Connell, A. W., Albert, M. S., Birren, J. E., Cotman, C. W., Greenough, W. T., Gold, P. E., Kramer, A. F., Kuller, L. H., et al. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.7.681 · Cited by 300
Deciphering the Genetic Basis of Alzheimer's Disease
Selkoe, D. J., & Podlisny, M. B. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.022502.103022 · Cited by 294
Self-citationSavage, M. J., Lin, Y.-G., Ciallella, J. R., Flood, D. G., & Scott, R. W. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03376.2002 · Cited by 291
“These transgenic animals were crossed with mice expressing a PS1 FAD knock-in mutation at P264L (Campion et al., 1995; Wasco et al., 1995).”
BackgroundInfluentialPodlisny, M. B., Citron, M., Amarante, P., Sherrington, R., Xia, W., Zhang, J., Diehl, T., Levesque, G., Fraser, P., Haass, C., et al. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0129 · Cited by 291
Self-citationSkovronsky, D. M., Doms, R. W., & Lee, V. M.-Y. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.4.1031 · Cited by 290
“…and FAD-associated PS1 and PS2 mutations have been shown to result in an increased ratio of Ab1-42/1-40 (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996), colocalization of the presenilins with a major site of constitutive Ab1-42 production raises the possibility that alterations…”
BackgroundInfluentialRogers, J. T., Leiter, L. M., McPhee, J., Cahill, C. M., Zhan, S.-S., Potter, H., & Nilsson, L. N. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6421 · Cited by 290
Genetic insights in Alzheimer's disease
Bettens, K., Sleegers, K., & Van Broeckhoven, C. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70259-4 · Cited by 290
High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model
Julien, C., Tremblay, C., Phivilay, A., Berthiaume, L., Émond, V., Julien, P., & Calon, F. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.022 · Cited by 288
Wnt signaling function in Alzheimer’s disease
De Ferrari and, G. V., & Inestrosa, N. C. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00021-7 · Cited by 289
Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer’s disease
Jia, L., Piña-Crespo, J., & Li, Y. (2019) · Molecular Brain · doi:10.1186/s13041-019-0525-5 · Cited by 288
Citron, M., Diehl, T. S., Gordon, G., Biere, A. L., Seubert, P., & Selkoe, D. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.13170 · Cited by 288
Self-citationAmyloid β-induced Changes in Nitric Oxide Production and Mitochondrial Activity Lead to Apoptosis
Keil, U., Bonert, A., Marques, C. A., Scherping, I., Weyermann, J., Strosznajder, J. B., Müller-Spahn, F., Haass, C., Czech, C., Pradier, L., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405600200 · Cited by 287
De Strooper, B., Beullens, M., Contreras, B., Levesque, L., Craessaerts, K., Cordell, B., Moechars, D., Bollen, M., Fraser, P., St. George-Hyslop, P., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3590 · Cited by 289
Expression of Presenilin 1 and 2 (PS1 and PS2) in Human and Murine Tissues
Lee, M. K., Slunt, H. H., Martin, L. J., Thinakaran, G., Kim, G., Gandy, S. E., Seeger, M., Koo, E., Price, D. L., & Sisodia, S. S. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-23-07513.1996 · Cited by 287
“In this regard, elevated levels of highly amyloidogenic -amyloid 1-42(43) have been reported in the plasma and conditioned medium of fibroblasts from individuals harboring PS1 or PS2 mutations (Scheuner et al., 1996).”
BackgroundDiverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production
Kukar, T., Murphy, M. P., Eriksen, J. L., Sagi, S. A., Weggen, S., Smith, T. E., Ladd, T., Khan, M. A., Kache, R., Beard, J., et al. (2005) · Nature Medicine · doi:10.1038/nm1235 · Cited by 284
Munter, L., Voigt, P., Harmeier, A., Kaden, D., Gottschalk, K. E., Weise, C., Pipkorn, R., Schaefer, M., Langosch, D., & Multhaup, G. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601616 · Cited by 285
Age-Dependent Neurodegeneration and Alzheimer-Amyloid Plaque Formation in Transgenic Drosophila
Greeve, I., Kretzschmar, D., Tschäpe, J.-A., Beyn, A., Brellinger, C., Schweizer, M., Nitsch, R. M., & Reifegerste, R. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0283-04.2004 · Cited by 287
“These FAD mutations are associated with altered APP processing and lead to an increased generation of amyloidogenic A 40 and A 42 peptides or to increased ratios of A 42 /A total (Lemere et al., 1996; Scheuner et al., 1996; Tomita et al., 1997).”
BackgroundAdvances in developing novel therapeutic strategies for Alzheimer’s disease
Cao, J., Hou, J., Ping, J., & Cai, D. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0299-8 · Cited by 285
The role of Aβ42 in Alzheimer's disease
Younkin, S. G. (1998) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(98)80035-1 · Cited by 282
Self-citationXia, W., Zhang, J., Kholodenko, D., Citron, M., Podlisny, M. B., Teplow, D. B., Haass, C., Seubert, P., Koo, E. H., & Selkoe, D. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.12.7977 · Cited by 284
Self-citationIntracellular Aβ42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease
Ohyagi, Y., Asahara, H., Chui, D.-H., Tsuruta, Y., Sakae, N., Miyoshi, K., Yamada, T., Kikuchi, H., Taniwaki, T., Murai, H., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2637fje · Cited by 281
Increasing Cu bioavailability inhibits Aβ oligomers and tau phosphorylation
Crouch, P. J., Hung, L. W., Adlard, P. A., Cortes, M., Lal, V., Filiz, G., Perez, K. A., Nurjono, M., Caragounis, A., Du, T., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809057106 · Cited by 278
“Structures of CuII(gtsm) [glyoxalbis(N (4)-methylthiosemicarbazonato)CuII] and CuII(atsm) [diacetylbis(N (4)-methyl-3-thiosemicarbazonato)CuII].”
Molecular genetics of Alzheimer’s disease
St George-Hyslop, P. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00301-7 · Cited by 265
Hansson, O., Zetterberg, H., Vanmechelen, E., Vanderstichele, H., Andreasson, U., Londos, E., Wallin, A., Minthon, L., & Blennow, K. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.03.027 · Cited by 281
Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
Goldsbury, C. S., Wirtz, S., Müller, S. A., Sunderji, S., Wicki, P., Aebi, U., & Frey, P. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4259 · Cited by 274
Cellular prion protein regulates β-secretase cleavage of the Alzheimer's amyloid precursor protein
Parkin, E. T., Watt, N. T., Hussain, I., Eckman, E. A., Eckman, C. B., Manson, J. C., Baybutt, H. N., Turner, A. J., & Hooper, N. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609621104 · Cited by 270
Self-citationLarson, J., Lynch, G., Games, D., & Seubert, P. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01698-4 · Cited by 275
Chiti, F., Calamai, M., Taddei, N., Stefani, M., Ramponi, G., & Dobson, C. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212527999 · Cited by 273
Exploring the Etiology of Alzheimer Disease Using Molecular Genetics
Lendon, C. L. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340059034 · Cited by 273
Slow Degradation of Aggregates of the Alzheimer's Disease Amyloid β-Protein by Microglial Cells
Paresce, D. M., Chung, H., & Maxfield, F. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.46.29390 · Cited by 271
Biomarkers of Alzheimer disease in plasma
Irizarry, M. C. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.226 · Cited by 268
“A 40 was elevated in a study of 78 AD and 61 control cases(10); however, most groups have found no significant differences between AD and control cases.(5,6,8,11,12) A 40 and sometimes A 42 levels correlated strongly with age and with serum creatinine levels.”
BackgroundCenteno, E. G. Z., Cimarosti, H., & Bithell, A. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0258-4 · Cited by 268
Wiltfang, J., Esselmann, H., Bibl, M., Smirnov, A., Otto, M., Paul, S., Schmidt, B., Klafki, H. ‐., Maler, M., Dyrks, T., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00818.x · Cited by 271
The Glutamatergic System and Alzheimer???s Disease: Therapeutic Implications
Butterfield, D. A., & Pocernich, C. B. (2003) · CNS Drugs · doi:10.2165/00023210-200317090-00004 · Cited by 267
Aβ-degrading enzymes: potential for treatment of Alzheimer disease
Miners, J. S., Barua, N., Kehoe, P. G., Gill, S., & Love, S. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182345e46 · Cited by 265
Alzheimer's Disease β-Amyloid Peptide Is Increased in Mice Deficient in Endothelin-converting Enzyme
Eckman, E. A., Watson, M., Marlow, L., Sambamurti, K., & Eckman, C. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200642200 · Cited by 218
Self-citationAlzheimer's disease: a re-examination of the amyloid hypothesis
Neve, R. L., & Robakis, N. K. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01168-5 · Cited by 256
Butterfield, D. A., Hardas, S. S., & Lange, M. L. B. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1375 · Cited by 262
Filamentous nerve cell inclusions in neurodegenerative diseases
Goedert, M., Spillantini, M. G., & Davies, S. W. (1998) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(98)80090-1 · Cited by 262
γ-Secretase Heterogeneity in the Aph1 Subunit: Relevance for Alzheimer’s Disease
Serneels, L., Van Biervliet, J., Craessaerts, K., Dejaegere, T., Horré, K., Van Houtvin, T., Esselmann, H., Paul, S., Schäfer, M. K., Berezovska, O., et al. (2009) · Science · doi:10.1126/science.1171176 · Cited by 260
Andersen, J. V., Schousboe, A., & Verkhratsky, A. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102331 · Cited by 250
Lorenzo, A., Yuan, M., Zhang, Z., Paganetti, P. A., Sturchler-Pierrat, C., Staufenbiel, M., Mautino, J., Vigo, F. S., Sommer, B., & Yankner, B. A. (2000) · Nature Neuroscience · doi:10.1038/74833 · Cited by 258
“These mutations alter the processing of APP, giving rise to increased production of Aβ or a 42-amino-acid form of Aβ with a high propensity for plaque formation, implicating altered APP processing in the pathogenesis of familial A”
BackgroundAge but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels
Fukumoto, H., Tennis, M., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.958 · Cited by 257
Larner, A. J., & Doran, M. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0019-5 · Cited by 256
“When stably transfected into cell lines, most PSEN1 mutations cause increased production of the longer variant of Aβ, Aβ42, [10, 35, 69, 89, 114, 147, 156, 157, 180] (but not all [4]).”
Apoptosis in Alzheimer's disease—an update
Shimohama, S. (2000) · Apoptosis · doi:10.1023/a:1009625323388 · Cited by 253
Presenilin-1 mutations and Alzheimer’s disease.
Kelleher, R. J., & Shen, J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619574114 · Cited by 255
APP Processing and Synaptic Plasticity in Presenilin-1 Conditional Knockout Mice
Yu, H., Saura, C. A., Choi, S.-Y., Sun, L. D., Yang, X., Handler, M., Kawarabayashi, T., Younkin, L., Fedeles, B., Wilson, M. A., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00417-2 · Cited by 256
Self-citationEstus, S., Tucker, H. M., van Rooyen, C., Wright, S., Brigham, E. F., Wogulis, M., & Rydel, R. E. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-20-07736.1997 · Cited by 258
“…that Ab aggregation may actually be causal in AD is suggested by findings that the known mutations associated with familial Alzheimer’s disease all lead to an increased production of the more amyloidogenic Ab1–42 (Citron et al., 1992; Cai et al., 1993; Suzuki et al., 1994; Scheuner et al., 1996).”
BackgroundOn the Seeding and Oligomerization of pGlu-Amyloid Peptides (in vitro)
Schilling, S., Lauber, T., Schaupp, M., Manhart, S., Scheel, E., Böhm, G., & Demuth, H.-U. (2006) · Biochemistry · doi:10.1021/bi0612667 · Cited by 254
Modulation of Secreted β-Amyloid Precursor Protein and Amyloid β-Peptide in Brain by Cholesterol
Howland, D. S., Trusko, S. P., Savage, M. J., Reaume, A. G., Lang, D. M., Hirsch, J. D., Maeda, N., Siman, R., Greenberg, B. D., Scott, R. W., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.26.16576 · Cited by 255
Amyloid‐β efflux from the central nervous system into the plasma
Roberts, K. F., Elbert, D. L., Kasten, T. P., Patterson, B. W., Sigurdson, W. C., Connors, R. E., Ovod, V., Munsell, L. Y., Mawuenyega, K. G., Miller‐Thomas, M. M., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24270 · Cited by 254
Structural Basis for Increased Toxicity of Pathological Aβ42:Aβ40 Ratios in Alzheimer Disease
Pauwels, K., Williams, T. L., Morris, K. L., Jonckheere, W., Vandersteen, A., Kelly, G., Schymkowitz, J., Rousseau, F., Pastore, A., Serpell, L. C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.264473 · Cited by 253
Biological markers for therapeutic trials in Alzheimer’s disease
Frank, R. A., Galasko, D., Hampel, H., Hardy, J., de Leon, M. J., Mehta, P. D., Rogers, J., Siemers, E., & Trojanowski, J. Q. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00002-2 · Cited by 252
“Aβ in plasma Studies have shown that plasma A 40 and A 42 levels were 2–3-fold higher in patients with familial AD and with presenilin mutations than sporadic AD and controls, and that A levels are approximately 100-fold lower in plasma than CSF [125].”
BackgroundSelf-citationAlpha‐synuclein in Lewy Body Disease and Alzheimer's Disease
Hashimoto, M., & Masliah, E. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00552.x · Cited by 254
Kimberly, W. T., Xia, W., Rahmati, T., Wolfe, M. S., & Selkoe, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.5.3173 · Cited by 253
Self-citationAmyloid-β as a Modulator of Synaptic Plasticity
Parihar, M. S., & Brewer, G. J. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101020 · Cited by 247
“Naturally occurring Aβ peptides can begin to assemble in vivo into metastable dimers, trimers and higher oligomers while still at low nanomolar levels [44,59,60].”
Bates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L., & Martins, R. N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.96 · Cited by 247
Amyloid β-Protein Monomer Folding: Free-Energy Surfaces Reveal Alloform-Specific Differences
Yang, M., & Teplow, D. B. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.09.039 · Cited by 247
Park, L., Anrather, J., Zhou, P., Frys, K., Pitstick, R., Younkin, S., Carlson, G. A., & Iadecola, C. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5207-04.2005 · Cited by 244
Self-citationThe genetics and neuropathology of Alzheimer’s disease
Schellenberg, G. D., & Montine, T. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0996-2 · Cited by 242
Self-citationHuang, X., Atwood, C. S., Moir, R. D., Hartshorn, M. A., Tanzi, R. E., & Bush, A. I. (2004) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-004-0602-8 · Cited by 242
Self-citationSaleem, S., & Kannan, R. R. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0109-7 · Cited by 239
Pappolla, M. A., Chyan, Y. J., Poeggeler, B., Frangione, B., Wilson, G., Ghiso, J., & Reiter, R. J. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050018 · Cited by 243
“In addition, some presenilin mutations appear to affect APP processing and enhance the rate of aggregation of Aâ by increasing the fraction of the more amyloidogenic peptide Aâ1–42 (Duff et al., 1996; Lemere et al., 1996; Scheuner et al., 1996).”
BackgroundCurrent and Emerging Drug Treatment Options for Alzheimerʼs Disease: A Systematic Review
Herrmann, N., Chau, S. A., Kircanski, I., & Lanctôt, K. L. (2011) · Drugs · doi:10.2165/11595870-000000000-00000 · Cited by 237
Urbanc, B., Cruz, L., Le, R., Sanders, J., Ashe, K. H., Duff, K., Stanley, H. E., Irizarry, M. C., & Hyman, B. T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222433299 · Cited by 237
Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics
Masters, C. L., Cappai, R., Barnham, K. J., & Villemagne, V. L. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03989.x · Cited by 241
“The main feature of the mutations in amyloid precursor protein, presenilin 1 and 2 is their involvement in the different steps of amyloid precursor protein processing pathway, which leads to increased production and elevated plasma levels of Ab, specially Ab42 (Scheuner et al. 1996).”
BackgroundInfluentialIncreased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers
Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005615 · Cited by 236
A New Pathogenic Mutation in the APP Gene (I716V) Increases the Relative Proportion of A 42(43)
Eckman, C. B., Mehta, N. D., Crook, R., Perez-tur, J., Prihar, G., Pfeiffer, E., Graff-Radford, N., Hinder, P., Yager, D., Zenk, B., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.12.2087 · Cited by 236
Self-citationPathogenesis of Alzheimer's disease.
Swerdlow, R. H. (2007) · PubMed Central · Cited by 329
Xia, W., Zhang, J., Perez, R., Koo, E. H., & Selkoe, D. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8208 · Cited by 238
Self-citationCalcium signaling in Alzheimer's disease & therapies
Tong, B. C.-K., Wu, A. J., Li, M., & Cheung, K.-H. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.07.018 · Cited by 231
Genetics of Alzheimer's Disease: A Centennial Review
Ertekin-Taner, N. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.009 · Cited by 234
“Analysis of plasma Aβ from affected families and the secreted Aβ from cell lines transfected with mutant forms of APP all showed an increase in the production of Aβ42± an increase in Aβ40; increased Aβ42/Aβ40 ratios or enhanced Aβ protofibril formation for all functionally assessed APP mutations [42, 76–80].”
BackgroundNimmrich, V., Grimm, C., Draguhn, A., Barghorn, S., Lehmann, A., Schoemaker, H., Hillen, H., Gross, G., Ebert, U., & Bruehl, C. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4771-07.2008 · Cited by 210
“Multiple lines of evidence suggest that A crucially contributes to the pathology of the disease (Scheuner et al., 1996; Bales et al., 1999).”
BackgroundNovel Research Horizons for Presenilins and γ-Secretases in Cell Biology and Disease
De Strooper, B., & Annaert, W. (2010) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100109-104117 · Cited by 234
Marzi, S. J., Leung, S. K., Ribarska, T., Hannon, E., Smith, A. R., Pishva, E., Poschmann, J., Moore, K., Troakes, C., Al-Sarraj, S., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0253-7 · Cited by 232
Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer’s disease.
LeBlanc, A., Liu, H., Goodyer, C., Bergeron, C., & Hammond, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23426 · Cited by 232
Kuo, Y.-M., Kokjohn, T. A., Kalback, W., Luehrs, D., Galasko, D. R., Chevallier, N., Koo, E. H., Emmerling, M. R., & Roher, A. E. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2222 · Cited by 230
Lichtenthaler, S. F., Haass, C., & Steiner, H. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07248.x · Cited by 205
“Even very subtle changes appear to be sufficient to cause the disease (Scheuner et al. 1996) by eliciting increased synaptic and cellular neurotoxicity (Kuperstein et al. 2010).”
BackgroundMehta, P. D., Pirttila, T., Patrick, B. A., Barshatzky, M., & Mehta, S. P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01754-2 · Cited by 231
Controlling Amyloid β-Peptide Fibril Formation with Protease-stable Ligands
Tjernberg, L. O., Lilliehöök, C., Callaway, D. J. E., Näslund, J., Hahne, S., Thyberg, J., Terenius, L., & Nordstedt, C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.19.12601 · Cited by 231
Williamson, R., Scales, T., Clark, B. R., Gibb, G., Reynolds, C. H., Kellie, S., Bird, I. N., Varndell, I. M., Sheppard, P. W., Everall, I., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-01-00010.2002 · Cited by 227
“All three genes, -amyloid precursor protein, presenilin 1, and presenilin 2, now known to cause AD have been shown to cause an increase in A production or an increase in the ratio of A 42/A 40, both of which drive aggregation (Scheuner et al., 1996; Citron et al., 1997).”
BackgroundPresenilin-1 Knockin Mice Reveal Loss-of-Function Mechanism for Familial Alzheimer’s Disease
Xia, D., Watanabe, H., Wu, B., Lee, S. H., Li, Y., Tsvetkov, E., Bolshakov, V. Y., Shen, J., & Kelleher, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.010 · Cited by 228
“FAD mutations in PSEN have been reported to increase A b 42 production selectively, suggesting that PSEN mutations may cause FAD via increased A b 42/A b 40 ratio (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996).”
Reactive oxygen species and Alzheimer's disease
Multhaup, G., Ruppert, T., Schlicksupp, A., Hesse, L., Beher, D., Masters, C. L., & Beyreuther, K. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00062-2 · Cited by 227
Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease
Schupf, N., Tang, M. X., Fukuyama, H., Manly, J., Andrews, H., Mehta, P., Ravetch, J., & Mayeux, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805902105 · Cited by 225
Wurth, C., Guimard, N. K., & Hecht, M. H. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00399-6 · Cited by 227
Ling, Y., Morgan, K., & Kalsheker, N. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(03)00133-x · Cited by 224
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.